Biogen Shares Decline After Detailed Diranersen Alzheimer's Study DataZacks Investment Research • 07/15/26
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 TranscriptSeeking Alpha • 07/14/26
Biogen Wins FDA Approval for Subcutaneous Starter Dose of LeqembiZacks Investment Research • 07/14/26
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of TreatmentPRNewsWire • 07/14/26
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's DiseaseGlobeNewsWire • 07/14/26
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's DiseasePRNewsWire • 07/13/26
Here Are Monday's Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John's International, Shopify, and More24/7 Wall Street • 07/13/26
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026PRNewsWire • 07/12/26
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.The Motley Fool • 07/04/26
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIBGlobeNewsWire • 06/29/26
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for DiranersenGlobeNewsWire • 06/29/26